Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteosarcoma Gene Therapy
Baylor College of Medicine, College of Medicine describes research in osteosarcoma gene therapy
August 12th, 2008
Data detailed in 'Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma' have been presented. According to recent research from the United States, "Osteosarcoma is a primary malignant tumor of bone arising from primitive bone-forming mesenchymal cells and accounts for approximately 60% of malignant bone tumors. Our comparative genomic hybridization (CGH) studies have identified frequent amplification at 6p12-p21, 12q13-q15, and 17p11.2 in osteosarcoma." "Of these amplified regions, 6p12-p21 is particularly interesting because of its association with progression and poor prognosis in patients with osteosarcoma. In an attempt to...
Source: Cancer Weekly (2008-08-12)
|
